Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adi Diab

Showing results (11-20 of 137) with videos related to

Pageof 14
Sort By:
Clinical Breast Cancer|January 17, 2018
Characteristics and Prognostic Factors for Patients With HER2-overexpressing Breast Cancer and Brain Metastases in the Era of HER2-targeted Therapy: An Argument for Earlier DetectionAki Morikawa, Rui Wang, Sujata Patil, et al.
Annals of the Rheumatic Diseases|August 24, 2017
Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case seriesSang Taek Kim, Jean Tayar, Van Anh Trinh, et al.
Neuro-Ophthalmology (Aeolus Press)|May 26, 2018
Metastatic Melanoma of the Optic Nerve SheathNeil M D'souza, Huy D Nguyen, Stacy V Smith, et al.
Cancers|November 14, 2023
Infliximab for Treatment of Immune Adverse Events and Its Impact on Tumor ResponseVishnupriyadevi Parvathareddy, Umut Selamet, Aditi A Sen, et al.
Journal for Immunotherapy of Cancer|May 12, 2018
Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD AndersonYinghong Wang, Hamzah Abu-Sbeih, Emily Mao, et al.
Kidney International Reports|January 16, 2026
Infliximab for Grade III or IV Immune Checkpoint Inhibitor Nephritis Clinical and Translational EvidenceNada Youssef, Masroor Habeeb, Hong Chen, et al.
Cancer|October 29, 2019
Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case seriesKourtney Holbrook, Jose Lutzky, Michael A Davies, et al.
Journal of Hematology & Oncology|September 7, 2016
Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn's disease: a case reportMarc Uemura, Van A Trinh, Cara Haymaker, et al.
Oncoimmunology|June 9, 2021
Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysisMaen Abdelrahim, Omar Mamlouk, Heather Lin, et al.
Cancer Immunology Research|April 19, 2019
IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from ImmunotherapyDaniel Johnson, Anisha B Patel, Marc I Uemura, et al.
Pageof 14

Showing results (11-20 of 137) with videos related to

Sort By:
Pageof 14
Clinical Breast Cancer|January 17, 2018
Characteristics and Prognostic Factors for Patients With HER2-overexpressing Breast Cancer and Brain Metastases in the Era of HER2-targeted Therapy: An Argument for Earlier DetectionAki Morikawa, Rui Wang, Sujata Patil, et al.
Annals of the Rheumatic Diseases|August 24, 2017
Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case seriesSang Taek Kim, Jean Tayar, Van Anh Trinh, et al.
Neuro-Ophthalmology (Aeolus Press)|May 26, 2018
Metastatic Melanoma of the Optic Nerve SheathNeil M D'souza, Huy D Nguyen, Stacy V Smith, et al.
Cancers|November 14, 2023
Infliximab for Treatment of Immune Adverse Events and Its Impact on Tumor ResponseVishnupriyadevi Parvathareddy, Umut Selamet, Aditi A Sen, et al.
Journal for Immunotherapy of Cancer|May 12, 2018
Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD AndersonYinghong Wang, Hamzah Abu-Sbeih, Emily Mao, et al.
Kidney International Reports|January 16, 2026
Infliximab for Grade III or IV Immune Checkpoint Inhibitor Nephritis Clinical and Translational EvidenceNada Youssef, Masroor Habeeb, Hong Chen, et al.
Cancer|October 29, 2019
Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case seriesKourtney Holbrook, Jose Lutzky, Michael A Davies, et al.
Journal of Hematology & Oncology|September 7, 2016
Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn's disease: a case reportMarc Uemura, Van A Trinh, Cara Haymaker, et al.
Oncoimmunology|June 9, 2021
Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysisMaen Abdelrahim, Omar Mamlouk, Heather Lin, et al.
Cancer Immunology Research|April 19, 2019
IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from ImmunotherapyDaniel Johnson, Anisha B Patel, Marc I Uemura, et al.
Pageof 14